Stock RCE RECCE PHARMACEUTICALS LTD
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Market Closed - Australian S.E.
Other stock markets
 07:10:13 28/06/2024 BST 		5-day change 1st Jan Change
0.6 AUD +5.26% Intraday chart for Recce Pharmaceuticals Ltd +0.84% +12.15%
02:51am Recce Pharmaceuticals' Phase 1/2 Urinary Tract Infection Trial Meets Primary Endpoints; Shares Up 4% MT
06-25 Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Recce Pharmaceuticals' Phase 1/2 Urinary Tract Infection Trial Meets Primary Endpoints; Shares Up 4%
MT
Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections
CI
Recce Pharmaceuticals Secures Ethics Approval for Bacterial Skin Infection Study
MT
Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization?S List of Antibacterial Products in Clinical Development
CI
Recce Pharmaceuticals Completes Dosing in Urosepsis Rapid Infusion Clinical Trial
MT
Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial
CI
Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial
MT
Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study
CI
Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study
MT
Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration
CI
Recce Pharmaceuticals Obtains China Patent for Anti-Infectives
MT
Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
CI
Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice
CI
Recce Pharmaceuticals Advances Production of Anti-Infective Medication
MT
Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives
CI
Recce Pharmaceuticals Secures Israeli Patent for Anti-Infective Medication; Shares Rise 5%
MT
Recce Pharmaceuticals Secures Canadian Trademark for Antibiotic Medications
MT
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis
CI
Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis
CI
Recce Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RCE Stock
  4. News Recce Pharmaceuticals Ltd
  5. Highlights